You may have noticed on our website: we have changed our logo this summer, and it is the most visible part of our strategic development. Of course, we are always experts in HCS and cell imaging but, for us, it is the perfect time to show our deep expertise in the critical point of the human health evolution in next years: the in vitro 3D cell culture as close as possible to real human organs.

With this new logo, we want to share our expertise on “organ-specific” in vitro 3D cell culture

2D cell culture often shows different results from those obtained in vivo in animals or Humans. HCS Pharma, thanks to its products BIOMIMESYS®, brings an innovative solution, more representative of in vivo conditions, an easy-to-use solution that is compatible with all analytical techniques.

BIOMIMESYS® “organ-specific” hydroscaffolds provide a culture microenvironment with the advantage of reproducing all aspects of human tissues, including matrix architecture, cellular organization, cell-cell and cell-matrix interactions. BIOMIMESYS® provides more predictive results. The composition is based on natural matrix components and is chemically controlled, which guarantees the reproducibility of your assays.

With its exclusive 3D cell culture technology BIOMIMESYS®, HCS Pharma becomes a key company in the 3D cell culture market and a key partner for the discovery and development of new drugs.

Do you want to know more about BIOMIMESYS®? Contact us!

Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

1 Comment

Artificial intelligence to improve 3D cell culture : a milestone for HCS pharma | · January 14, 2021 at 2:39 pm

[…] you may now, in HCS Pharma we strongly believe that the critical point of the human health evolution in next years is the in vitro 3D cell culture, especially for complex diseases like cancer [1]. It’s why we […]

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.